Physician profile
Grisel Lagunas
NPI 1306937727
$10,397.02
in general payments reported to CMS, 2019-2025
21 companies · $1,119 in 2025
The $1,119 reported for 2025 was more than what 92% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,523 · 2020: $394 · 2021: $1,398 · 2022: $1,091 · 2023: $2,641 · 2024: $1,232 · 2025: $1,119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,787 · Travel and Lodging: $622 · Entertainment: $583.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,786.59 |
| Travel and Lodging | $622.07 |
| Entertainment | $582.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,971.72 | 2019-2025 | Precision 1, Precision7, Total30 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $2,111.20 | 2019-2020 | |
| Coopervision INC. | $1,368.09 | 2019-2024 | Misight Contact Lens, Myday Contact Lens |
| Optos, INC. | $1,206.19 | 2019-2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Sight Sciences, INC. | $528.60 | 2019-2024 | Tearcare System |
| Abb Con-Cise Optical Group LLC | $470.43 | 2021-2024 | Contact Lens, Spectacle Lenses |
| Lkc Technologies, INC. | $242.12 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $239.40 | 2020-2022 | |
| Bausch & Lomb Americas INC. | $199.00 | 2023-2024 | Infuse |
| Maculogix, INC. | $179.45 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $150.86 | 2022-2023 | Acuvue |
| Topcon Healthcare, INC. | $143.91 | 2021 | |
| Astellas Pharma US INC | $132.71 | 2025 | Izervay |
| Allergan, INC. | $109.17 | 2022 | |
| Apellis Pharmaceuticals, INC. | $90.38 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $86.04 | 2019-2025 | |
| Carl Zeiss Meditec USA, INC. | $84.85 | 2021 | |
| Synergeyes, INC. | $28.09 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $21.66 | 2025 | Xdemvy |
| Lombart Brothers, INC. | $17.53 | 2023 | Opd-III |
| Oyster Point Pharma, INC. | $15.62 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grisel Lagunas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.